Development of novel, centrally active GLYT1 inhibitors that further validate the nmda hypofunction hypothesis of schizophrenia in preclinical animal models

被引：0
|
作者：
Lindsley, C. [1 ]
机构：
[1] Merck Res Labs, West Point, PA USA
来源：
SCHIZOPHRENIA BULLETIN | 2007年 / 33卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：475 / 475
页数：1
相关论文
共 15 条
  • [1] Progress towards validation of the NMDA hypofunction hypothesis of schizophrenia: Discovery and development of centrally active glycine transporter (GlyT1) inhibitors
    Lindsley, Craig W.
    Hartman, George D.
    Williams, David L.
    Sur, Cyrille
    O'Brien, Julie
    Lemaire, Wei
    Chang, Raymond S.
    Kinney, Gene G.
    Pettibone, Douglas J.
    Duggan, Mark E.
    Zhao, Zhijian
    Burno, Maryann
    Conn, P. J.
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S25 - S25
  • [2] DEVELOPMENT OF GLYT1 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA
    Schmidt, Christopher
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 114 - 114
  • [3] Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors
    Pinard, Emmanuel
    Alberati, Daniela
    Bender, Markus
    Borroni, Edilio
    Brom, Virginie
    Burner, Serge
    Fischer, Holger
    Hainzl, Dominik
    Halm, Remy
    Hauser, Nicole
    Jolidon, Synese
    Lengyel, Judith
    Marty, Hans-Peter
    Meyer, Thierry
    Moreau, Jean-Luc
    Mory, Roland
    Narquizian, Robert
    Norcross, Roger D.
    Schmid, Philipp
    Wermuth, Roger
    Zimmerli, Daniel
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (23) : 6960 - 6965
  • [4] Effects of SSR103800, a novel GlyT1 inhibitor, on the behavior of NMDA NO hypomorphic mice, a model of schizophrenia
    Boulay, D.
    Pichat, P.
    Bergis, O.
    Avenet, P.
    Griebel, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S478 - S479
  • [5] Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
    Rosenbrock, Holger
    Desch, Michael
    Wunderlich, Glen
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2023, 273 (07) : 1557 - 1566
  • [6] Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
    Holger Rosenbrock
    Michael Desch
    Glen Wunderlich
    European Archives of Psychiatry and Clinical Neuroscience, 2023, 273 : 1557 - 1566
  • [7] Pharmacological Characterization of the Novel GlyT1 Inhibitor BI 425809 on Target Engagement in-vivo and in Animal Models Related to Cognitive Symptoms of Schizophrenia
    Rosenbrock, Holger
    Giovannini, Riccardo
    Schmid, Bernhard
    Kramer, Gert
    Arban, Roberto
    Dorner-Ciossek, Cornelia
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 343S - 343S
  • [8] Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat
    Black, Mark D.
    Varty, Geoffrey B.
    Arad, Michal
    Barak, Segev
    De Levie, Amaya
    Boulay, Denis
    Pichat, Philippe
    Griebel, Guy
    Weiner, Ina
    PSYCHOPHARMACOLOGY, 2009, 202 (1-3) : 385 - 396
  • [9] Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat
    Mark D. Black
    Geoffrey B. Varty
    Michal Arad
    Segev Barak
    Amaya De Levie
    Denis Boulay
    Philippe Pichat
    Guy Griebel
    Ina Weiner
    Psychopharmacology, 2009, 202 : 385 - 396
  • [10] 3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors
    Pinard, Emmanuel
    Alberati, Daniela
    Alvarez-Sanchez, Ruben
    Brom, Virginie
    Burner, Serge
    Fischer, Holger
    Hauser, Nicole
    Kolczewski, Sabine
    Lengyel, Judith
    Mory, Roland
    Saladin, Christian
    Schulz-Gasch, Tanja
    Stalder, Henri
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (04): : 428 - 433
12